Rossari Biotech posts record Q2FY27 revenue of Rs. 697.6 crore, up 19.0%; board approves KSA greenfield land lease
Q2FY27 revenue up 19.0% to record Rs. 697.6 crore, EBITDA up 20.9% to Rs. 87.0 crore; PAT Rs. 38.9 crore held back by depreciation.
By ScoutQuest · · 1 min read
- Q2FY27 revenue
- Rs. 697.6 crore, up 19.0% year on year
- EBITDA
- up 20.9% to Rs. 87.0 crore
- PAT
- rose only 5.4% to Rs. 38.9 crore
- Period
- Q2 & H1 FY27
- Positioning
- Rossari describes itself as a specialty chemicals maker spanning HPPC, textile and animal health, transitioning from a domestic manufacturer into a globally integrated solutions provider, with FY26 revenue 74% domestic and 26% export.
📈 Q2FY27 revenue from operations was Rs. 697.6 crore, up 19.0% year on year, and EBITDA Rs. 87.0 crore with margin at 12.5%. PAT rose only 5.4% to Rs. 38.9 crore as depreciation climbed to 30.1 crore from 18.2 crore and finance costs to 8.7 crore. H1FY27 revenue was Rs. 1,394.8 crore, up 23.5%.
📉 Export sales hit a record Rs. 216.4 crore, up 33.8%. The company says operating cash flow was Rs. 131 crore, net working capital improved to 86 days from 97 days, and net debt fell to Rs. 221 crore from Rs. 281 crore as of March 2026.
🏭 Management states it is moving from a domestic specialty chemicals manufacturer to a globally integrated solutions provider. The board approved leasing land through a wholly owned KSA subsidiary for a greenfield plant, and the company has commissioned a 5,000 MTPA blending facility in Thailand.
🏭 The presentation lists five growth strategies: accelerating core lines through cross-sell and wallet share, innovation, using newly commissioned brownfield capacity in India, strengthening international distribution and building new growth platforms. FY26 revenue was Rs. 2,396.4 crore with PAT of Rs. 149.2 crore.
Also from Rossari Biotech
Earnings call: record quarterly revenue and EBITDA; Board approves land lease for Saudi greenfield plant
23 Oct 2026
Rossari Biotech files audio recording of Q2 & H1 FY27 earnings conference call held October 19, 2026
19 Oct 2026
Rossari Biotech reported strong quarter two earnings driven by higher exports and improved margins, even as the stock fell 3.5 percent despite the good numbers
19 Oct 2026
More numbers
- Revenue from operations, Q2FY27Rs. 697.6 crores
- Revenue growth YoY, Q2FY2719.0%
- EBITDA, Q2FY27Rs. 87.0 crores
- PAT, Q2FY27Rs. 38.9 crores
- Export sales, Q2FY27Rs. 216.4 crores
- Cash flow from operations, H1FY27Rs. 131 crores
- Net debt, September 2026Rs. 221 crores
- Net working capital, September 202686 days
- Revenue from operations, H1FY271,394.8 (INR in crores)
- Depreciation and amortization, Q2FY2730.1 (INR in crores)
- Revenue from operations, FY262,396.4 (INR in crores)
- PAT, FY26149.2 (INR in crores)
- Export share of revenue, FY2626%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.